Live flu vaccine trial

By Kate McDonald
Friday, 27 February, 2009

Melbourne’s BioDiem and Schering-Plough’s vaccine business unit Nobilon have begun a clinical development program for BioDiem’s intranasal live attenuated influenza vaccine (LAIV).

The vaccine, named SCH 900795, is composed of three attenuated flu viruses that will be delivered in a single-dose intranasal spray.

The Phase I study will test the safety, tolerability and immunogenicity of the vaccine in 120 healthy volunteers.

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Content from other channels on our network

Nestlé launches on-pack date-labelling pilot to help tackle food waste

Handling the protein powder boom: engineering solutions for powder processing

Seafood safety researcher awarded at NZIFST Food Industry Awards

Blade innovation reduces the cost of slicing and dicing

Hygienic Design in Practice: Supporting Modern Food Production

Energy crisis will have long‍-‍term effects: Australian Industry Group

Myriota launches hybrid 5G satellite and cellular IoT network

Funding program for smaller businesses to access additive manufacturing

Collaboration provides NZ's largest smart water meter upgrade

ARENA backs Sicona battery technology to boost EV performance

Demand increases for skilled sustainability professionals

Pilot program reduces food waste in SEQ

Yarra Valley Water to report net zero operational emissions

Recycling workers' lives at risk from hazardous waste

Biochar used for solar water purification